Amgen Company Profile (NASDAQ:AMGN)

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AMGN
  • CUSIP: 03116210
  • Web:
  • Market Cap: $132.72784 billion
  • Outstanding Shares: 729,674,000
Average Prices:
  • 50 Day Moving Avg: $183.93
  • 200 Day Moving Avg: $170.98
  • 52 Week Range: $133.64 - $191.10
  • Trailing P/E Ratio: 16.96
  • Foreward P/E Ratio: 14.60
  • P/E Growth: 3.30
Sales & Book Value:
  • Annual Revenue: $23.05 billion
  • Price / Sales: 5.89
  • Book Value: $43.41 per share
  • Price / Book: 4.29
  • Annual Dividend: $4.60
  • Dividend Yield: 2.5%
  • EBITDA: $12.36 billion
  • Net Margins: 35.46%
  • Return on Equity: 29.85%
  • Return on Assets: 11.72%
  • Debt-to-Equity Ratio: 1.06%
  • Current Ratio: 6.20%
  • Quick Ratio: 5.82%
  • Average Volume: 2.49 million shs.
  • Beta: 1.36
  • Short Ratio: 2.81

Frequently Asked Questions for Amgen (NASDAQ:AMGN)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Friday, July 28th. Stockholders of record on Thursday, August 17th will be paid a dividend of $1.15 per share on Friday, September 8th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.47%. The ex-dividend date is Tuesday, August 15th. View Amgen's Dividend History.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, July, 25th. The company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to analysts' expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm's quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.84 earnings per share. View Amgen's Earnings History.

When will Amgen make its next earnings announcement?

Amgen is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY17 earnings guidance on Monday, September, 25th. The company provided earnings per share (EPS) guidance of $12.15-12.65 for the period, compared to the Thomson Reuters consensus estimate of $12.56. The company issued revenue guidance of $22.5-23.0 billion, compared to the consensus revenue estimate of $22.85 billion.

Where is Amgen's stock going? Where will Amgen's stock price be in 2017?

20 brokerages have issued 1-year price targets for Amgen's stock. Their forecasts range from $161.00 to $210.00. On average, they anticipate Amgen's share price to reach $191.11 in the next twelve months. View Analyst Ratings for Amgen.

What are analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • 1. According to Zacks Investment Research, "Amgen is well positioned for growth with several blockbuster drugs in its portfolio. Amgen’s newer drugs – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are all performing well. Additionally, Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline, including biosimilar drugs. Amgen’s shares have outperformed the industry so far this year. However, the company has some challenges in store, given the presence of biosimilar competition and slowdown in sales of mature products. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. Meanwhile, uptake of Repatha has been slow due to payer restrictions. Estimates have gone up ahead of the company’s Q3 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (10/16/2017)
  • 2. Cann analysts commented, "Amgen yesterday announced that the Journal of Clinical Oncology has published positive results from the Imlygic (talimogene laherparepvec) phase II ‘264 study, demonstrating a doubling of response rate or better in the Imlygic combination arm. The data published yesterday in JCO are encouraging, and these along with results from ongoing studies could lead to unexpected adoption of Imlygic and provide upside to our sales estimates. These data demonstrated that Imlygic has a dramatic effect in combination with Yervoy, and the combination looks as strong a much of the reference data for other combinations." (10/6/2017)
  • 3. Mizuho analysts commented, "We are increasing our AMGN price target from $183 to $198 on the back of the biotech sector having re-rated somewhat post the GILD/KITE acquisition. We have not changed our estimates." (9/28/2017)
  • 4. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
  • 5. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)

Are investors shorting Amgen?

Amgen saw a increase in short interest in September. As of September 15th, there was short interest totalling 9,412,565 shares, an increase of 29.5% from the August 31st total of 7,267,419 shares. Based on an average trading volume of 3,016,948 shares, the days-to-cover ratio is currently 3.1 days. Currently, 1.3% of the company's stock are short sold.

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:

  • Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
  • David W. Meline, Executive Vice President, Chief Financial Officer
  • Sean E. Harper, Executive Vice President - Research and Development
  • Anthony C. Hooper, Executive Vice President - Global Commercial Operations
  • Brian M. McNamee, Executive Vice President - Full Potential Initiatives
  • Esteban Santos, Executive Vice President, Operations
  • Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
  • Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
  • Lori A. Johnston, Senior Vice President
  • David A. Piacquad, Senior Vice President - Business Development

Who owns Amgen stock?

Amgen's stock is owned by many different of institutional and retail investors. Top institutional investors include Beacon Financial Group (0.01%), Eqis Capital Management Inc. (0.00%), Fulton Bank N.A. (0.00%), Park National Corp OH (0.00%), Bridges Investment Counsel Inc. (0.00%) and Curbstone Financial Management Corp (0.00%). Company insiders that own Amgen stock include Annette Louise Such, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including Bridges Investment Counsel Inc., Private Asset Management Inc., Fulton Bank N.A. and Park National Corp OH. Company insiders that have sold Amgen stock in the last year include Cynthia M Patton and Sean E Harper. View Insider Buying and Selling for Amgen.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was acquired by a variety of institutional investors in the last quarter, including Beacon Financial Group, Curbstone Financial Management Corp and Eqis Capital Management Inc.. View Insider Buying and Selling for Amgen.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of Amgen stock can currently be purchased for approximately $186.19.

MarketBeat Community Rating for Amgen (NASDAQ AMGN)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  987 (Vote Outperform)
Underperform Votes:  596 (Vote Underperform)
Total Votes:  1,583
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 10 Hold Ratings, 9 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $191.11 (2.64% upside)
Consensus Price Target History for Amgen (NASDAQ:AMGN)
Price Target History for Amgen (NASDAQ:AMGN)
Analysts' Ratings History for Amgen (NASDAQ:AMGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017Barclays PLCBoost Price TargetEqual Weight$180.00 -> $190.00N/AView Rating Details
10/6/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$203.00N/AView Rating Details
10/6/2017MizuhoReiterated RatingBuy$198.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$189.00 -> $196.00N/AView Rating Details
10/6/2017CannReiterated RatingBuy$203.00N/AView Rating Details
10/5/2017Bank of America CorporationBoost Price TargetBuy$210.00N/AView Rating Details
9/29/2017Credit Suisse GroupReiterated RatingNeutral$177.00 -> $186.00MediumView Rating Details
9/25/2017Jefferies Group LLCReiterated RatingBuy$200.00LowView Rating Details
9/25/2017BMO Capital MarketsReiterated RatingHold$199.00LowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$192.00HighView Rating Details
7/27/2017ArgusBoost Price TargetBuy$180.00 -> $195.00LowView Rating Details
7/26/2017Deutsche Bank AGReiterated RatingHold$172.00 -> $174.00LowView Rating Details
7/22/2017Cowen and CompanyReiterated RatingOutperform$209.00LowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$161.00LowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
3/20/2017Goldman Sachs Group, Inc. (The)Lower Price TargetConviction-Buy$208.00 -> $202.00LowView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$193.00LowView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
9/28/2016Citigroup Inc.Lower Price TargetNeutral$175.00 -> $172.00N/AView Rating Details
9/28/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00N/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingHoldN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Amgen (NASDAQ:AMGN)
Earnings by Quarter for Amgen (NASDAQ:AMGN)
Earnings History by Quarter for Amgen (NASDAQ AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$3.11N/AView Earnings Details
7/25/2017Q2 2017$3.11$3.27$5.67 billion$5.81 billionViewN/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.60 billion$5.46 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amgen (NASDAQ:AMGN)
2017 EPS Consensus Estimate: $12.28
2018 EPS Consensus Estimate: $12.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$3.04$3.17$3.09
Q2 20173$3.05$3.12$3.09
Q3 20173$3.01$3.19$3.12
Q4 20173$2.96$2.99$2.98
Q1 20181$3.29$3.29$3.29
Q2 20181$3.18$3.18$3.18
Q3 20181$3.10$3.10$3.10
Q4 20181$3.10$3.10$3.10
(Data provided by Zacks Investment Research)


Current Dividend Information for Amgen (NASDAQ:AMGN)
Most Recent Dividend:9/8/2017
Annual Dividend:$4.60
Dividend Yield:2.47%
Dividend Growth:28.60% (3 Year Average)
Payout Ratio:41.93% (Trailing 12 Months of Earnings)
36.80% (Based on This Year's Estimates)
36.08% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Dividend History by Quarter for Amgen (NASDAQ AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Amgen (NASDAQ:AMGN)
Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 78.08%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/9/2017Sean E HarperEVPSell1,525$185.95$283,573.75View SEC Filing  
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.80View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amgen (NASDAQ:AMGN)
Latest Headlines for Amgen (NASDAQ:AMGN)
DateHeadline logoAmgen Inc. (AMGN) Set to Announce Earnings on Wednesday - October 18 at 2:58 AM logoValue System: Amgen Looks Undervalued - Seeking Alpha - October 18 at 2:45 AM logoTechnician says this one hot sector is about to heat up - October 17 at 9:44 PM logoZacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen - October 17 at 4:41 PM logo Analysts Expect Amgen Inc. (AMGN) Will Announce Quarterly Sales of $5.73 Billion - October 17 at 8:12 AM logoQ3 2017 EPS Estimates for Amgen Inc. (AMGN) Increased by Analyst - October 17 at 7:48 AM logoPharma Industry Outlook - October 2017 - October 16 at 9:41 PM logoAmgen teams up with Boston Children's Hospital to identify new pain targets - October 16 at 4:46 PM logoAmgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes - October 16 at 4:39 PM logoIndustry Group Rank Metrics Keep Amgen (AMGN) Ratings Upgrade to Hold - October 16 at 1:47 PM logoAnalyzing Amgen (AMGN) and The Competition - October 16 at 4:32 AM logoBarclays PLC Increases Amgen Inc. (AMGN) Price Target to $190.00 - October 13 at 7:02 PM logoCan Biotech Stay Healthy Through the End of 2017? - October 13 at 3:15 PM logoAmgen Puerto Rico Staff Keeping Plant Open Despite Personal Losses From Hurricane Maria - October 12 at 4:37 PM logoAmgen Foundation Awards Khan Academy $3 Million To Support Development Of Free Comprehensive Biology Lessons - October 12 at 4:37 PM logoComparing Amgen (AMGN) & The Competition - October 12 at 4:24 PM logoDow's Merck Bails On Cholesterol Drug, Prodding Shares Down - October 11 at 10:23 PM logoBiotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit - October 11 at 5:22 PM logoMylan Receives CRL for Neulasta Biosimilar - October 11 at 5:22 PM logoAmgen Inc. Expected to Earn Q3 2017 Earnings of $3.16 Per Share (AMGN) - October 11 at 7:37 AM logoSean E. Harper Sells 1,525 Shares of Amgen Inc. (AMGN) Stock - October 10 at 10:28 PM logoAmgen Wins Reprieve on Its 2nd-Best-Selling Drug - Motley Fool - October 10 at 10:12 PM logoIf Approved, Aimovig Could Strengthen Amgen’s Neurology Portfolio - October 10 at 5:10 PM logoAmgen’s Pipeline Could Boost Its Long-Term Growth Opportunities - October 10 at 5:10 PM logoTezepelumab Could Help Amgen Develop Its Inflammation Franchise - October 10 at 5:10 PM logoAmgen Label Expansion Application for Prolia Accepted by FDA - October 10 at 5:10 PM logo5 Stocks To Watch For October 10, 2017 - October 10 at 5:42 AM logoAmgen: FDA Accepts SBLA For Prolia - October 10 at 2:54 AM logoFDA accepts Amgen's marketing application for expanded use of osteoporosis med Prolia, action date May 28, 2018 - October 9 at 4:52 PM logoRepatha Could Be Amgen’s Long-Term Growth Driver - October 9 at 4:50 PM logoBiosimilars Could Boost Amgen’s Revenue Growth - October 9 at 4:50 PM logo[$$] Ruling Goes Regeneron's Way - October 9 at 4:50 PM logoFDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis - October 9 at 4:50 PM logoAmgen’s (AMGN) Raised to Hold - October 9 at 12:32 PM logoAmgen’s (AMGN) Raised to Hold - October 9 at 12:31 PM logoAmgen Sees Unusually Large Options Volume (AMGN) - October 8 at 1:40 AM logoAmgen Inc. (AMGN) Stock Rating Reaffirmed by Morgan Stanley - October 7 at 1:04 PM logoAmgen Inc. (AMGN) Has Spiked To The Downside - October 6 at 9:09 PM logoFirst Randomized Study To Evaluate IMLYGIC® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology - October 6 at 9:09 PM logoToday's Research Reports on Stocks to Watch: Amgen and Regeneron - October 6 at 9:09 PM logoFDA: Drug shortages possible due to Puerto Rico power outage - October 6 at 9:09 PM logoAmgen's (AMGN) Buy Rating Reiterated at Mizuho - October 6 at 8:32 PM logoUpdates On The PCSK9 Inhibitor Legal And Pipeline Scene - Seeking Alpha - October 6 at 4:07 PM logoWhy Regeneron's Patent Win Is Worse For Amgen Than You Think - October 6 at 4:07 PM logoAmgen And LabCentral Open Nomination Process For Lab Residency - October 6 at 4:07 PM logoAmgen's (AMGN) Buy Rating Reaffirmed at Oppenheimer Holdings, Inc. - October 6 at 3:04 PM logoAmgen's (AMGN) "Buy" Rating Reaffirmed at Cann - October 6 at 9:12 AM logoAmgen Inc. (AMGN) Price Target Raised to $210.00 - October 5 at 1:32 PM logoCytomX stock rockets 35% after deal with Amgen - MarketWatch - October 5 at 1:27 PM logoAmgen 'Disappointed' In Court Decision To Reverse Praluent Sales Ban - Benzinga - October 5 at 1:27 PM



Amgen (AMGN) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.